BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 15762770)

  • 1. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
    Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
    Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
    Zhou S; Chan E; Lim LY; Boelsterli UA; Li SC; Wang J; Zhang Q; Huang M; Xu A
    Curr Drug Metab; 2004 Oct; 5(5):415-42. PubMed ID: 15544435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
    Zhou SF
    Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
    Dresser GK; Spence JD; Bailey DG
    Clin Pharmacokinet; 2000 Jan; 38(1):41-57. PubMed ID: 10668858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.
    Zhou SF; Xue CC; Yu XQ; Li C; Wang G
    Ther Drug Monit; 2007 Dec; 29(6):687-710. PubMed ID: 18043468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
    Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
    Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition.
    Zhang X; Jones DR; Hall SD
    Drug Metab Dispos; 2009 Jan; 37(1):150-60. PubMed ID: 18854379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4.
    Zhou SF
    Curr Pharm Des; 2008; 14(10):990-1000. PubMed ID: 18473851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4.
    Chan WK; Delucchi AB
    Life Sci; 2000 Nov; 67(25):3103-12. PubMed ID: 11125847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
    Wen X; Wang JS; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.
    Rowland Yeo K; Walsky RL; Jamei M; Rostami-Hodjegan A; Tucker GT
    Eur J Pharm Sci; 2011 Jun; 43(3):160-73. PubMed ID: 21540107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
    Mueck W; Kubitza D; Becka M
    Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.
    McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE
    Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes.
    Potęga A; Fedejko-Kap B; Mazerska Z
    Pharmacol Rep; 2016 Aug; 68(4):663-70. PubMed ID: 27110874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.
    Mayhew BS; Jones DR; Hall SD
    Drug Metab Dispos; 2000 Sep; 28(9):1031-7. PubMed ID: 10950845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
    Ohno Y; Hisaka A; Suzuki H
    Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4.
    Burt HJ; Pertinez H; Säll C; Collins C; Hyland R; Houston JB; Galetin A
    Drug Metab Dispos; 2012 Sep; 40(9):1658-67. PubMed ID: 22621802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.
    Zhou S; Chan E; Li X; Huang M
    Ther Clin Risk Manag; 2005 Mar; 1(1):3-13. PubMed ID: 18360537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.